Advertisement

Topics

Adaptimmune's NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients

13:01 EDT 20 Jul 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Data Published in Nature Medicine PHILADELPHIA and OXFORD, England, July 20, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today a...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Adaptimmune's NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...